Please login to the form below

Not currently logged in
Email:
Password:

Transcept Pharmaceuticals names Leone Patterson as chief financial officer

She joins with experience in the finance departments of Novartis and Exelixis

Leone Patterson has joined US-based specialty pharmaceutical Transcept Pharmaceuticals as VP and chief financial officer.

She succeeds Thomas Soloway, who has been promoted to executive VP and chief operating officer, and in her new role will have primary responsibility for all finance functions at neuroscience specialists Transcept.

Patterson joins from Net App, a publicly held data storage company, where she was VP and corporate controller.

Prior to this role, she was VP of finance at Exelixis, a biotech company focused on the development of cancer therapies.

She has also spent time at Swiss pharma giant Novartis, serving as VP of global business planning analysis in the company's vaccines and diagnostics division.

"Leone brings to Transcept a broad background in business planning and financial management," noted Glenn Oclassen, president and CEO.

"She is an important addition to our executive team and we look forward to her contributions.”

Transcept finally managed to clear insomnia drug Intermezzo in the US in November, 2011, after twice being turned down by the Food and Drug Administration (FDA).

The company is also developing a low-dose form of GlaxoSmithKline's Zofran (ondansetron) called TO-2061. It is in phase II studies as an adjunctive therapy in patients with obsessive compulsive disorder (OCD) who have not adequately responded to approved first-line therapy.

28th June 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
C+D

C+D has been informing, supporting and championing community pharmacy for more than 150 years. As an award-winning multi-media publisher we...

Latest intelligence

A new reality for healthcare
When mobile phones came onto the mass market it would have been difficult to see how they were to develop into the ubiquitous multimedia devices they are now. Their power,...
Digital-green-grey.jpg
Are you getting these benefits from your digital technology?
Your organisation switched from ‘paper to glass’, buying the latest mobile devices and hiring digital agencies to fill them with eye-catching content. But what happened?...
Alzheimer's: the numbers we cannot forget
In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Infographics